Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Deremer

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|April 24, 2023
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK InhibitorsDavid L DeRemer, Bently P Doonan
The Annals of Pharmacotherapy|April 3, 2024
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast CancerAlexa J Luboff, David L DeRemer
The Annals of Pharmacotherapy|May 28, 2025
Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal AdenocarcinomaGabrielle L Gorwitz, David L DeRemer
The Annals of Pharmacotherapy|August 24, 2017
The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial CarcinomaMorgan E Gwynn, David L DeRemer
Cancer Management and Research|May 11, 2011
Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemiaDavid L Deremer, Katerina Katsanevas, Celalettin Ustun
Clinical Therapeutics|December 26, 2008
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaDavid L Deremer, Celalettin Ustun, Kavita Natarajan
Leukemia Research|June 7, 2011
Tyrosine kinase inhibitors in the treatment of systemic mastocytosisCelalettin Ustun, David L DeRemer, Cem Akin
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 8, 2013
Romiplostim resistance in secondary failure of platelet recoveryDavid L DeRemer, Katerina Katsanevas, Amber Bradley, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 3, 2014
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?Amber Bradley Clemmons, Sarah Evans, David L DeRemer, et al.
Expert Opinion on Investigational Drugs|August 13, 2009
Investigational drugs targeting FLT3 for leukemiaCelalettin Ustun, David L DeRemer, Anand P Jillella, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|April 24, 2023
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK InhibitorsDavid L DeRemer, Bently P Doonan
The Annals of Pharmacotherapy|April 3, 2024
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast CancerAlexa J Luboff, David L DeRemer
The Annals of Pharmacotherapy|May 28, 2025
Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal AdenocarcinomaGabrielle L Gorwitz, David L DeRemer
The Annals of Pharmacotherapy|August 24, 2017
The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial CarcinomaMorgan E Gwynn, David L DeRemer
Cancer Management and Research|May 11, 2011
Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemiaDavid L Deremer, Katerina Katsanevas, Celalettin Ustun
Clinical Therapeutics|December 26, 2008
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaDavid L Deremer, Celalettin Ustun, Kavita Natarajan
Leukemia Research|June 7, 2011
Tyrosine kinase inhibitors in the treatment of systemic mastocytosisCelalettin Ustun, David L DeRemer, Cem Akin
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 8, 2013
Romiplostim resistance in secondary failure of platelet recoveryDavid L DeRemer, Katerina Katsanevas, Amber Bradley, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 3, 2014
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?Amber Bradley Clemmons, Sarah Evans, David L DeRemer, et al.
Expert Opinion on Investigational Drugs|August 13, 2009
Investigational drugs targeting FLT3 for leukemiaCelalettin Ustun, David L DeRemer, Anand P Jillella, et al.
Pageof 5